CCA
STOK icon

Cygnus Capital Advisors’s Stoke Therapeutics STOK Stock Holding History

Cygnus Capital Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49 Sell
1,500
-1,500
-50% -$49.2K 0.03% 74
2025
Q4 		$95 Buy
+3,000
New +$90.2K 0.07% 60

Other funds holding STOK

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Cygnus Capital Advisors's STOK Position: Q1 2026 in Review

Cygnus Capital Advisors reduced its Stoke Therapeutics (STOK) stake by 50% in Q1 2026, selling an estimated $49.2K and leaving 1,500 shares worth $49. The position accounts for 0.03% of the portfolio, ranked #74.

Cygnus Capital Advisors first reported a position in STOK in Q4 2025 and has held it in 2 quarters since. The position peaked at $95 in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Cygnus Capital Advisors held 1,500 shares of Stoke Therapeutics worth $49 as of Q1 2026.
  • Cygnus Capital Advisors sold 1,500 Stoke Therapeutics shares in Q1 2026, an estimated $49.2K.
  • Stoke Therapeutics made up 0.03% of Cygnus Capital Advisors's portfolio in Q1 2026, its #74 holding.
  • Cygnus Capital Advisors first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Cygnus Capital Advisors's Stoke Therapeutics position peaked at $95 in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.